Molecular Insight reports improved $3.27 million net loss for March

By Caroline Salls

Pittsburgh, April 20 - Molecular Insight Pharmaceuticals, Inc. reported a $3.27 million net loss for March on $332,570 in grant revenue, according to its monthly operating report filed Wednesday with the Securities and Exchange Commission.

The figures showed improvement over the $3.72 million net loss posted for February on $95,727 in grant revenue.

The company had $6.97 million in cash and cash equivalents at March 31, down from $10.66 million at the end of February.

Molecular Insight, a Cambridge, Mass.-based clinical-stage biopharmaceutical company focused on molecular medicine, filed for bankruptcy on Dec. 9 in the U.S. Bankruptcy Court for the District of Massachusetts. The Chapter 11 case number is 10-23355.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.